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Background: The purpose of this study was to determine whether the provision of corticosteroids improves time
to shock reversal and outcomes in patients with post-cardiac arrest shock.
Methods: We conducted a randomized, double-blind trial of post-cardiac arrest patients in shock, defined as
vasopressor support for a minimum of 1 hour. Patients were randomized to intravenous hydrocortisone 100 mg or
placebo every 8 hours for 7 days or until shock reversal. The primary endpoint was time to shock reversal.
Results: Fifty patients were included with 25 in each group. There was no difference in time to shock reversal
between groups (hazard ratio: 0.83 [95 % CI: 0.40–1.75], p = 0.63). We found no difference in secondary outcomes
including shock reversal (52 % vs. 60 %, p = 0.57), good neurological outcome (24 % vs. 32 %, p = 0.53) or survival to
discharge (28 % vs. 36 %, p = 0.54) between the hydrocortisone and placebo groups. Of the patients with a baseline
cortisol < 15 ug/dL, 100 % (6/6) in the hydrocortisone group achieved shock reversal compared to 33 % (1/3) in the
placebo group (p = 0.08). All patients in the placebo group died (100 %; 3/3) whereas 50 % (3/6) died in the
hydrocortisone group (p = 0.43).
Conclusions: In a population of cardiac arrest patients with vasopressor-dependent shock, treatment with
hydrocortisone did not improve time to shock reversal, rate of shock reversal, or clinical outcomes when
compared to placebo.
Clinical trial registration: Clinicaltrials.gov: NCT00676585, registration date: May 9, 2008.
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Cardiac arrest occurs in over 400,000 patients in the
United States each year [1], and the overall mortality for
cardiac arrest remains dismal with a survival rate less
than 10 % [1]. In an attempt to improve survival and
quality of life, international cardiac arrest guidelines
emphasize not only the importance of optimizing intra-* Correspondence: mdonnino@bidmc.harvard.edu
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during the post-cardiac arrest period [2–4]. Unfortunately,
due to a paucity of studies investigating new medical
treatments, clinicians have little to offer to post-cardiac
arrest patients other than supportive care and temperature
management [5].
Adrenal insufficiency is common in critical illness and
post-cardiac arrest and is associated with poor outcome
[6–12]. Adrenal insufficiency in the post-cardiac arrest
state can be explained by multiple pathophysiological
mechanisms including ischemia/reperfusion injury of the
adrenal glands, increased metabolic demand, and the on-
going systemic inflammatory response after the cardiacle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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ciency and hemodynamic compromise has been estab-
lished in primary adrenal insufficiency. Corticosteroids,
while controversial, are currently suggested in patients
with refractory septic shock as a mean of reducing time
to shock reversal and potentially improving mortality
[14–16]. Previous studies have demonstrated multiple
similarities between the post-cardiac arrest shock state
and that of septic shock [12, 17–19]. Thus, a physiologic
rationale exists for the potential efficacy of corticosteroid
therapy in post-cardiac arrest patients with shock. Both the
International Liaison Committee on Resuscitation (ILCOR)
[20] and the American Heart Association (AHA) [5] state
that the utility of corticosteroids remains unknown and
that a critical knowledge gap exists in this area.
We hypothesized that the administration of hydrocor-
tisone to post-cardiac arrest patients in refractory shock
would improve hemodynamics leading to more rapid
shock reversal and ultimately improvement in survival.
Methods
Study design
We conducted a multi-center, double-blind, randomized,
placebo-controlled trial of hydrocortisone in post-cardiac
arrest patients in shock. The study was conducted at
Beth Israel Deaconess Medical Center (BIDMC), MA, USA
(coordinating site), Wayne State Medical Center, MI, USA
and Baystate Medical Center, MA, USA. The Committee
on Clinical Investigations at BIDMC (2007-P-000227),
Wayne State University Human Investigation Committee
(082108MP2F) and the Institutional Review Board at
Baystate Medical Center (132387) approved the study. The
trial was registered at clinicaltrials.gov (NCT00676585). All
patients were consented and enrolled via legal authorized
representatives. Drs. Donnino and Andersen had full
access to all the data in the study and take responsibility
for the integrity of the data and the accuracy of the
data analysis.
Patients and intervention
The emergency department and intensive care units
were screened for eligible patients between January 2008
and March 2014. We included patients if they met all of
the following criteria: age ≥ 18 years, out-of-hospital or
in-hospital cardiac arrest, and post-cardiac arrest vasopres-
sor dependence for at least 1 hour. We defined vasopressor
dependence as a continuous infusion of norepinephrine,
dopamine (≥5 mcg/kg/min), vasopressin (>0.04 units/min),
phenylephrine and/or epinephrine. Dobutamine or other
inotropes at any dose were not considered vasopressor
dependence. We excluded patients if they met one or
more of the following criteria: (1) vasopressor dependence
before the cardiac arrest, (2) chronic use of steroids prior
to the cardiac arrest, (3) clinical indication for steroids orprovision of steroids by the clinical team, (4) “do-not-
resuscitate” (DNR) or “comfort measures only” (CMO)
designation prior to enrollment, and (5) inability to obtain
consent.
Patients were randomized in a 1:1 ratio to either
hydrocortisone or placebo. The intervention consisted
of intravenous hydrocortisone 100 mg every 8 hours
for a total of 7 days or until 24 hours after shock re-
versal. The placebo was identical in appearance to the
active treatment and patients, healthcare personnel
and the research team remained blinded throughout
the study period.
Outcomes and data collection
The primary outcome was time to shock reversal defined
as at least 24 hours off all vasopressor medications [21].
Secondary outcomes included shock reversal (yes/no),
cytokine levels (see below), the cumulative vasopressor
dose within 24 hours, and mortality and good neuro-
logical outcome at hospital discharge. Neurological out-
come was defined using the cerebral performance
category (CPC) scale, which ranges from 1 (normal) to 5
(brain death) [22]. We considered a CPC of 1 or 2 a
“good neurologic outcome” and a CPC of 3, 4 or 5 and
death a “poor neurologic outcome” consistent with pre-
vious cardiac arrest investigations [23–25]. The cumula-
tive vasopressor dose was calculated as the total dose of
vasopressors within the first 24 hours after study drug
administration. Since different vasopressors have different
potency we used the following formula: cumulative
vasopressor dose (μg/kg) = norepinephrine (μg/kg) +
dopamine/2 (μg/kg) + epinephrine (μg/kg) + phenyleph-
rine/10 (μg/kg) as previously used [26–28].
Cosyntropin test and cytokines
An adrenocorticotropic hormone (cosyntropin) stimula-
tion test was performed immediately before the first
dose of the study medication: cosyntropin (250 μg) was
administered immediately after an initial blood draw and
then blood was drawn again 30 and 60 minutes there-
after. Cortisol levels were measured in all these samples.
After the 60-minute draw, the study medication was ad-
ministered. Adrenal insufficiency was defined in two
ways: absolute: baseline cortisol < 15 ug/dL and relative:
< 9 ug/dL increase at 30 minutes or 60 minutes (using
the highest value) after the cosyntropin test as compared
to baseline, consistent with previous literature.
Additional blood draws for cytokine measurements
were obtained 24 hours after the study drug administra-
tion. Plasma samples were analyzed for interleukin (IL)-
6 and IL-10 using a customized Meso Scale Discovery
(MSD) Human Multiplex Panel (Rockville, MD, USA)
according to the manufacturer’s protocol. IL-6 and IL-10
are measured in pg/mL.
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We determined that a sample size of 50 patients (25
per group) would yield 86 % power based on the following
assumptions: the survival distributions followed an ex-
ponential function and the median time to event for
the placebo group was 33 hours and 13 hours for the
hydrocortisone group with a follow-up period of 7 days.
The type I error rate was set at 0.05 and we used a two-
sided test with the Lakatos normal approximation for the
log-rank test.
The study population was characterized using descrip-
tive statistics; categorical variables are provided as
counts with frequencies and continuous variables as
means with standard deviations (SD) or medians with
quartiles depending on the normality of the data.
The primary endpoint of time to shock reversal was
complicated by a high incidence of death prior to rever-
sal of shock. To account for this we classified death as a
competing risk event and used the estimated cumulative
incidence function (CIF) to illustrate the comparison of
CIFs between the two treatment groups. These esti-
mated CIF functions were derived from the estimation
of the Fine-Gray competing risk model [29]. We tested
the sub-distribution hazards of these two CIFs and ob-
tained the estimated hazard ratio with 95 % confidence
intervals.
Given that cytokine values were severely right-skewed,
we log-transformed them before analysis and then
compared values between the groups with a t test.
Differences between groups (hydrocortisone vs. placebo)
in other outcomes were evaluated using Fisher’s exact test
for categorical variables, and two-sample t tests or
Wilcoxon rank-sum tests for continuous variables.
Preplanned subgroup analyses were performed in
those with baseline absolute and relative adrenal insuffi-
ciency. All hypothesis tests were two-sided, with a sig-
nificance level of p < 0.05. We performed no adjustment
for multiple comparisons and all secondary analysis
should therefore be considered exploratory. Statistical
analyses were conducted with the use of SAS software,
version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
Fifty patients were included; 25 received hydrocortisone
and 25 received placebo. Forty-eight patients were en-
rolled at the coordinating site. No patients were lost to
follow-up and no patients had the study drug stopped
prematurely or required unblinding. The mean age for
the complete study population was 69 (SD: 14) years
and 17 (34 %) were female. The majority of patients
(38 [76 %]) had an out-of-hospital cardiac arrest and 34
(68 %) died before hospital discharge. Baseline characteris-
tics for each group are presented in Table 1. The groupswere well matched on baseline characteristics except for a
higher frequency of hypertension in the placebo group
and a higher frequency of renal disease in the hydrocorti-
sone group.
Clinical and safety outcomes
There was no difference in the primary outcome of time
to shock reversal between the groups (hazard ratio: 0.83
[95 % CI: 0.40–1.75], p = 0.63). There was no difference
in shock reversal (13 [52 %] vs. 15 [60 %], p = 0.78), good
neurological outcome (6 [24 %] vs. 8 [32 %], p = 0.75) or
survival to discharge (7 [28 %] vs. 9 [36 %], p = 0.76) be-
tween the hydrocortisone and placebo groups. Three
(12 %) patients in the hydrocortisone group and four
(16 %) in the placebo group died within 24 hours of study
drug administration (p = 0.68). There was no difference
between the two groups in the mode of death (p = 0.92,
Table 2). The cumulative vasopressor dose within the first
24 hours was calculated on 47 patients with available data
(24 in the hydrocortisone group and 23 in the placebo
group). There was no difference in the cumulative vaso-
pressor dose between the hydrocortisone and placebo
groups (842 μg/kg [418, 3120] vs. 437 μg/kg [170, 4237],
p = 0.62) during the first 24 hours. In patients who
achieved shock reversal (i.e., excluding those who died
while on vasopressors), there was no difference in the time
to shock reversal between the hydrocortisone and placebo
groups (55 hours [30, 59] vs. 49 [25, 71] hours, p = 0.86).
Potential adverse events and selected laboratory values
are presented in Table 3. There was no difference in
bleeding, administration of new antibiotics or adminis-
tration of an insulin infusion between the hydrocortisone
and placebo groups. Glucose and sodium levels were
similar between the two treatment groups at 6, 24, 48,
and 72 hours after initiation of study drug. There was no
difference in the white blood cell count between groups
at 6 or 24 hours, however patients who received hydro-
cortisone had higher white blood cell count at 48 and
72 hours after administration of the study drug.
Cytokines
Thirty-seven patients had cytokine levels measured at the
24-hour time point and were included in the analysis; 19
in the hydrocortisone group and 18 in the placebo group.
Patients in the hydrocortisone group had significantly
lower log-transformed IL-6 levels at the 24-hour time
point as compared to the placebo group (3.14 [SD: 2.00]
vs. 4.97 [SD: 1.96], p = 0.008, Fig. 1). There was no differ-
ence in log-transformed IL-10 levels (1.89 [SD: 1.57] vs.
1.31 [SD: 1.22], p = 0.22, Fig. 1) at the 24-hour time point.
Patients with adrenal insufficiency
Baseline cortisol levels were available on 47 patients and
46 had follow-up cortisol levels. Nine patients had
Table 1 Selected baseline characteristics of the study patientsa
Characteristic Hydrocortisone (n = 25) Placebo (n = 25)
Demographics
Age (years) 71 (13) 66 (15)
Sex (female) 9 (36) 8 (32)
Race (white) 21 (84) 18 (78)
Co-morbidities
Coronary artery disease 11 (44) 9 (36)
Congestive heart failure 6 (24) 8 (32)
Hyperlipidemia 7 (28) 9 (36)
Hypertension 11 (44) 19 (76)
Chronic obstructive pulmonary disease 2 (8) 1 (4)
Diabetes 5 (20) 6 (24)
Liver disease 0 (0) 0 (0)
Renal disease 6 (24) 2 (8)
Cancer 2 (8) 1 (4)
Location of the arrest
In-hospital 6 (24) 6 (24)
Out-of-hospital 19 (76) 19 (76)
Arrest characteristics
Initial rhythm (shockable) 9 (36) 10 (40)
Downtime (minutes) 21 (10, 30) 16 (10, 38)
Presumed cause of the arrest
Primary cardiac 13 (52) 12 (48)
Pulmonary embolism 1 (4) 1 (4)
Respiratory 5 (20) 6 (24)
Metabolic/electrolyte 2 (8) 1 (4)
Sepsis 1 (4) 0 (0)
Other/unknown 3 (12) 5 (20)
Vital signs at enrollment
Heart rate 84 (18) 82 (21)
Systolic blood pressure 103 (97, 132) 109 (93, 130)
Diastolic blood pressure 61 (51, 70) 59 (48, 67)
Respiratory rate 22 (5) 23 (5)
Glasgow coma scale 3 (3, 6) 3 (3, 4)
Laboratory values at enrollment
Lactate (mmol/L) 2.8 (1.9, 5.3) 3.9 (1.9, 6.5)
Glucose (mg/dL) 237 (108) 226 (99)
pH 7.25 (0.14) 7.24 (0.13)
Time from ROSC to study drug (hours) 9.9 (7.3, 19.6) 12.7 (7.8, 15.6)
Time from start of vasopressor(s) to study drug (hours) 9.7 (6.3, 18.0) 11.4 (7.5, 15.0)
APACHE II score at enrollment 29 (5) 30 (7)
Induced hypothermia 19 (76) 16 (64)
ROSC return of spontaneous circulation, APACHE Acute Physiology and Chronic Health Evaluation
aCategorical variables are presented as count (frequency) and continues variables as mean (standard deviation) or median (quartiles) depending on the normality
of the data. Data missing on one patient for downtime, one patient for Glasgow coma score, one patient for pH, one patient for lactate, two patients for glucose
and one patient on time from start of vasopressors to study drug
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Refractory shock 1 (6) 1 (6)
Sudden cardiac arrest 2 (11) 2 (13)
Co-morbid disease withdrawal of care 3 (17) 1 (6)
Primary neurological withdrawal of care 12 (67) 11 (69)
Other/unknown 0 (0) 1 (6)
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tisone group and three in the placebo group). The
sample size in this subgroup was too small to per-
form the competing risk analysis. All six patients
(100 %) in the hydrocortisone group had shock rever-
sal as compared to one patient (33 %) in the placebo
group (p = 0.08). There was no difference in the pro-
portion of patients with good neurological outcome
(2 [33 %] vs. 0 [0 %], p = 0.50) or survival to hospital
discharge (3 [50 %] vs. 0 [0 %], p = 0.46) between the
hydrocortisone and placebo groups.
Twenty-one patients had relative adrenal insufficiency
(11 in the hydrocortisone group and 10 in the placebo







Adverse event after study drug
Any bleeding 5 (20 %) 2 (9 %) 0.42
New or changed antibiotics 9 (36 %) 11 (44 %) 0.77
New insulin infusion 7 (28 %) 6 (24 %) 1.00
Laboratory values
Glucose level (mg/dL)
6 hour 242 (151) 230 (118) 0.76
24 hour 218 (109) 199 (90) 0.54
48 hour 163 (50) 155 (59) 0.66
72 hour 150 (52) 144 (61) 0.79
Sodium level (mmol/L)
6 hour 139 (5) 139 (6) 0.78
24 hour 139 (5) 138 (5) 0.37
48 hour 139 (7) 139 (5) 0.80
72 hour 143 (6) 139 (8) 0.09
White blood count (x 103)
6 hour 15.0 (6.9) 17.0 (6.7) 0.43
24 hour 17.8 (8.7) 15.5 (4.7) 0.29
48 hour 21.5 (9.3) 12.6 (3.4) <0.001
72 hour 19.2 (8.8) 11.9 (2.9) 0.005
aCategorical variables are presented as count (frequency) and continues
variables as mean (standard deviation)[27 %] vs. 6 [60 %], p = 0.20), good neurological out-
come (1 [18 %] vs. 4 [20 %], p = 0.36), or survival to
hospital discharge (3 [27 %] vs. 4 [40 %], p = 0.66)
between the hydrocortisone and placebo groups in
this subgroup of patients.
Discussion
In this study, we found no difference in time to shock
reversal or other clinical outcomes in post-cardiac arrest
patients with shock receiving hydrocortisone compared
to placebo. While the corticosteroid group displayed in-
creased white cell counts at 48 and 72 hours, we did not
detect any significant differences in the side effect pro-
files between the groups. To the best of our knowledge,
this is the first randomized trial to specifically evaluate the
efficacy of hydrocortisone in the post-cardiac arrest patient
population [5, 20].
The post-cardiac arrest syndrome is characterized by a
variety of pathophysiological features similar to septic
shock states including a systemic inflammatory response
and hemodynamic perturbations, which may include
microcirculatory dysfunction and myocardial suppression
[17, 19, 30, 31]. Corticosteroid therapy in this setting
could work via both immunologic and hemodynamic
mechanisms. Corticosteroids are known to modulate the
systemic inflammatory response [32, 33] and animal
models have shown preserved myocardial function and
improvement of arterial reactivity with the administration
of physiological doses of corticosteroids [34, 35]. Despite
the physiological rationale for corticosteroid therapy
in this patient population and the fact that the utility
of corticosteroids have been relatively well studied in
the setting of septic shock [36], there is a lack of research
on the efficacy of corticosteroids in post-cardiac arrest
patients [5, 20].
A recent study by Mentzelopoulos et al. examined the
effects of corticosteroids and vasopressin during and
after in-hospital cardiac arrest. In this study, patients
who received vasopressin and methylprednisolone during
the cardiac arrest and hydrocortisone in the post-arrest
period (if in shock) had improved clinical outcomes [37].
There are multiple potential explanations for the differ-
ences between studies. First, and most importantly,
the study by Mentzelopoulos et al. included multiple
interventions in the treatment arm both during and
after the cardiac arrest. As such, it is difficult to make
firm conclusions about any specific interventions [38].
Second, the patient populations differ substantially be-
tween studies (for example, we enrolled 76 % out-of-
hospital arrest patients whereas Mentzelopoulos et al.
enrolled only inpatients). Lastly, the sample size in
the current study may have been too small to detect
a significant difference between groups. In light of our
findings, we believe that the provision of post-cardiac
Fig. 1 Cytokine levels at 24 hours. Log-transformed interleukin (IL)-6 (left) and IL-10 (right) levels 24 hours after study drug administration. There
was significantly lower IL-6 levels at 24 hours in the hydrocortisone group compared to the placebo group (p = 0.008) but no difference in IL-10
levels (p = 0.22). The dots indicate the means and the error bars the standard deviation
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los et al. trial protocol would need to be specifically evalu-
ated even if the full protocol were validated.
Multiple studies have examined adrenal insufficiency
in the post-cardiac arrest population [8–12]. Although
some inconsistency exists between these studies, they
have generally found that impaired adrenal function is
common [8] and that both low baseline cortisol levels
[9, 10] and impaired cortisol response to adrenocortico-
tropic hormone stimulation are associated with poor out-
comes [11, 12]. One study found that cortisol levels are
rarely checked in patients with vasopressor-dependent
shock post-cardiac arrest [8]. Out of a total group of 69
patients in that study, cortisol levels were only measured
in nine (13 %) and corticosteroids were provided for the
indication of shock in 12 (17 %) [8]. In the current study,
we found that nine (18 %) of included patients had abso-
lute baseline cortisol deficiency (<15 ug/dL) and 21 (42 %)
had relative adrenal insufficiency. Although we did not
find any significant differences in outcomes between those
receiving hydrocortisone and placebo in these subgroups,
we did see a nonsignificant difference in shock reversal in
those with absolute adrenal insufficiency with six patients
(100 %) in the hydrocortisone group having shock reversal
as compared to one patient (33 %) in the placebo group
(p = 0.08). Future studies may determine whether these
patients could benefit from corticosteroid therapy.
Corticosteroids are well known to modulate the im-
mune system and could theoretically have an effect on
the post-cardiac arrest inflammatory response. In our
study, we found that IL-6 levels were decreased in the
hydrocortisone group as compared to the placebo group
at 24 hours. We and others have previously reported
that increased IL-6 levels measured after cardiac arrest
are associated with increased mortality and worse neuro-
logical outcome [39–41]. While hydrocortisone attenu-
ated IL-6 levels, there were no associated differences in
clinical outcomes. These findings raise the possibilitythat IL-6 elevation after arrest may be an epiphenom-
enon and not necessarily in the causal pathway of per-
sistent or ongoing injury. For reasons that remain
unclear, we did not find any difference between groups
in IL-10 levels, though IL-10 is considered to be an anti-
inflammatory cytokine.
Our study has several limitations. First, the heterogen-
eity of our study population may not have allowed for
assessment of subsets of patients that would be more or
less likely to benefit from corticosteroids, or may have
led to inclusion of population for which the ultimate
outcome was less modifiable given baseline injury sever-
ity. Second, we found that the majority of patients suc-
cumbed to death from neurological causes and not
hemodynamic compromise. In contrast, corticosteroids
would theoretically be most efficacious in a population
that has a higher burden of death from cardiovascular
causes (i.e., refractory hemodynamic shock). That stated,
we did not find that hydrocortisone led to a more rapid
shock reversal or increased rate of shock reversal in this
trial. Third, the numbers of patients with either relative
or absolute adrenal insufficiency was too small for de-
finitive conclusions in this important subgroup. Future
study is necessary to help identify the value of cortico-
steroids in the deficient population, and our data sug-
gests that a reasonable target population might be
patients with a baseline cortisol < 15 ug/dL as opposed to
those who fail to increase cortisol levels by 9 ug/dl with a
cosyntropin stimulation test. The timing of corticosteroids
may influence outcome, and this intervention could theor-
etically be beneficial earlier (i.e., just after return of spon-
taneous circulation in order to prevent subsequent injury)
or later (i.e., after 24 hours hypothetically in the subset
with adrenal exhaustion). Differing dosages, duration, or
ways of providing (i.e., continuous versus intermittent in-
fusion) may have impacted the findings. Finally, although
three sites were enrolling patients, the vast majority of pa-
tients (48) were enrolled at the coordinating site.
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Hydrocortisone compared to placebo did not decrease
time to shock reversal or improve overall shock reversal
in post-cardiac arrest patients in shock.
Key messages
 Until now, the effectiveness of corticosteroids in
post-cardiac arrest patients with vasopressor-
dependent shock is unknown
 We conducted a randomized, double-blind,
placebo-controlled pilot trial of corticosteroids in
post-cardiac arrest patients in shock
 In the overall population of patients with shock
post-cardiac arrest, corticosteroids did not improve
shock reversal or other clinical outcomes
 For the overall population of patients with shock
post-cardiac arrest, corticosteroids did attenuate
inflammation as represented by interleukin-6 levels
 For the subpopulation of patients with baseline
adrenal insufficiency, corticosteroids had a
near-significant improvement in shock reversal
compared to placebo, though future studies with
larger number of patients will be needed to evaluate
this population.
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